ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Last trade$1.01
Day change+$0.005 (+0.50%)
Day range$0.956 – $1.03
Volume264,747
Market cap$138M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$138.28M
Price / earnings
—
Price / book
1.02×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.52×
Profitability
Earnings per share
-$0.58
Return on assets
-50.3%
Return on equity
-59.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.07×
Current ratio
9.71×
Quick ratio
9.71×
Cash ratio
1.54×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$70.95M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALXO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.13M
$5.36M
$5.38M
$5.09M
$5.45M
$7.93M
$7.08M
$6.1M
Research and development
$13.14M
$13.61M
$17.65M
$17.44M
$18.02M
$23.89M
$23.53M
$26.47M
Total operating expenses
$18.03M
$18.97M
$23.02M
$22.53M
$26.65M
$31.82M
$30.61M
$32.57M
Operating income
-$18.03M
-$18.97M
-$23.02M
-$22.53M
-$26.65M
-$31.82M
-$30.61M
-$32.57M
Interest expense
-$285K
-$331K
-$383K
-$408K
-$405K
-$406K
-$427K
-$446K
Income before taxes
-$17.97M
-$17.93M
-$22.85M
-$22.14M
-$25.95M
-$30.75M
-$29.16M
-$30.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$17.97M
-$17.93M
-$22.85M
-$22.14M
-$25.95M
-$30.75M
-$29.16M
-$30.71M
Net income attributable to common shareholders
-$17.97M
-$17.93M
-$22.85M
-$22.14M
-$25.95M
-$30.75M
-$29.16M
-$30.71M
EBITDA
-$18.19M
-$18.82M
-$22.87M
-$22.38M
-$23.28M
-$31.61M
-$30.4M
-$32.34M
Basic earnings per share
-$0.13
-$0.17
-$0.42
-$0.41
-$0.49
-$0.58
-$0.54
-$0.58
Diluted earnings per share
-$0.13
-$0.17
-$0.42
-$0.41
-$0.49
-$0.58
-$0.54
-$0.58
Recent news
Company coverage with links to the original publishers.
ALX Oncology reported Q4 2025 financial results with improved net losses and announced strong clinical progress for its lead candidates evorpacept and ALX2004. The company validated CD47 as a predictive biomarker for evorpacept response in cancer trials, completed a $150 million equity offering extending cash runway through H1 2028, and appointed Barbara Klencke as permanent Chief Medical Officer. Multiple clinical milestones are anticipated over the next 12-18 months.
ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 trials.
ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.
The HER2-positive gastric cancer market is experiencing sustained growth, with over 20 companies developing novel targeted therapies, driven by advances in precision medicine and expanded HER2 testing.
ALX Oncology will participate in two healthcare conferences in November and December 2025, presenting their ongoing clinical-stage cancer therapies, including lead candidate evorpacept and new pipeline candidate ALX2004.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.